Determinants of the Cost of Health Services Used by Veterans With HIV

BackgroundThe effect of adherence, treatment failure, and comorbidities on the cost of HIV care is not well understood. ObjectiveTo characterize the cost of HIV care including combination antiretroviral treatment (ART). Research DesignObservational study of administrative data. SubjectsTotal 1896 randomly selected HIV-infected patients and 288 trial participants with multidrug-resistant HIV seen at the US Veterans Health Administration (VHA). MeasuresComorbidities, cost, pharmacy, and laboratory data. ResultsMany HIV-infected patients (24.5%) of the random sample did not receive ART. Outpatient pharmacy accounted for 62.8% of the costs of patients highly adherent with ART, 32.2% of the cost of those with lower adherence, and 6.2% of the cost of those not receiving ART. Compared with patients not receiving ART, high adherence was associated with lower hospital cost, but no greater total cost. Individuals with a low CD4 count (<50 cells/mm3) incurred 1.9 times the cost of patients with counts >500. Most patients had medical, psychiatric, or substance abuse comorbidities. These conditions were associated with greater cost. Trial participants were less likely to have psychiatric and substance abuse comorbidities than the random sample of VHA patients with HIV. ConclusionsPatients receiving combination ART had higher medication costs but lower acute hospital cost. Poor control of HIV was associated with higher cost. The cost of psychiatric, substance abuse, rehabilitation, and long-term care and medications other than ART, often overlooked in HIV studies, was substantial.

[1]  Richard D Moore,et al.  Contemporary costs of HIV healthcare in the HAART era , 2010, AIDS.

[2]  E. Beck,et al.  The cost of treatment and care for people living with HIV infection: implications of published studies, 1999–2008 , 2010, Current opinion in HIV and AIDS.

[3]  M. Freeland,et al.  “An Overview of the NHEA With Implications for Cost Analysis Researchers” , 2009, Medical care.

[4]  M J Gill,et al.  Cost of medical care for HIV‐infected patients within a regional population from 1997 to 2006 , 2008, HIV medicine.

[5]  A. Justice,et al.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Guo,et al.  Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005 , 2007, AIDS research and therapy.

[7]  F. Hellinger.  The Changing Pattern of Hospital Care for Persons Living With HIV: 2000 Through 2004 , 2007, Journal of acquired immune deficiency syndromes.

[8]  A. Hill,et al.  Analysis of Treatment Costs for HIV RNA Reductions and CD4 Increases for Darunavir Versus Other Antiretrovirals in Treatment-Experienced, HIV–Infected Patients , 2007, HIV clinical trials.

[9]  R. Weinstein,et al.  The cost of care for patients with HIV from the provider economic perspective. , 2006, AIDS patient care and STDs.

[10]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.

[11]  Jerome H. Carter,et al.  Distribution of health care expenditures for HIV-infected patients. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  A. Levy,et al.  The direct costs of HIV/AIDS care. , 2006, The Lancet. Infectious diseases.

[13]  T. Wagner,et al.  The relationships among age, chronic conditions, and healthcare costs. , 2004, The American journal of managed care.

[14]  R. Gross,et al.  A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. , 2004, Journal of clinical epidemiology.

[15]  W. Encinosa,et al.  Antiretroviral therapy and health care utilization: a study of privately insured men and women with HIV disease. , 2004, Health services research.

[16]  Y. Lo,et al.  Gender and Hospitalization Patterns Among HIV‐Infected Drug Users Before and After the Availability of Highly Active Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.

[17]  A. Rothbard,et al.  Cost of care for Medicaid recipients with serious mental illness and HIV infection or AIDS. , 2003, Psychiatric services.

[18]  T. Wagner,et al.  Using Average Cost Methods to Estimate Encounter-Level Costs for Medical-Surgical Stays in the VA , 2003, Medical care research and review : MCRR.

[19]  Wei Yu,et al.  Estimating the Costs of VA Ambulatory Care , 2003, Medical care research and review : MCRR.

[20]  J. Singer,et al.  An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. , 2003, Controlled clinical trials.

[21]  M. Render,et al.  Methods for Estimating and Comparing VA Outpatient Drug Benefits With the Private Sector , 2003, Medical care.

[22]  A R Willan,et al.  Cost prediction models for the comparison of two groups. , 2001, Health economics.

[23]  D. McCaffrey,et al.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, The New England journal of medicine.

[24]  W. Manning,et al.  Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.

[25]  M. Holodniy,et al.  Decreased Medical Expenditures for Care of HIV-Seropositive Patients , 1999, PharmacoEconomics.

[26]  Richard D Moore,et al.  Costs of HIV medical care in the era of highly active antiretroviral therapy. , 1999, AIDS.

[27]  B. Yip,et al.  Modelling the Potential Economic Impact of Viral Load—Driven Triple Drug Combination Antiretroviral Therapy , 1998, PharmacoEconomics.

[28]  D B Rubin,et al.  Multiple imputation in health-care databases: an overview and some applications. , 1991, Statistics in medicine.

[29]  D. Cox,et al.  An Analysis of Transformations , 1964 .

[30]  P. Farnham.  Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment? , 2010, Applied health economics and health policy.

[31]  C. Rietmeijer,et al.  The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care , 2008, Applied health economics and health policy.

[32]  F. Hellinger.  Economic models of antiretroviral therapy: searching for the optimal strategy. , 2006, PharmacoEconomics (Auckland).

[33]  J. Reisch,et al.  Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.